Serina Therapeutics, based in Alameda, California, is a clinical-stage biotechnology company developing drug candidates for neurological diseases, focusing on SER-252 for Parkinson's Disease. The company went public on November 29, 2018, and employs four people.
SER filed a patent for "targeting of antigen-presenting cells by nanoparticles containing polyoxazoline-lipid conjugates" on Fri, January 20, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
